



Purilin®

Levosalbutamol Sulphate INN

Description

Levosalbutamol (Purilin®) is a single isomer beta-2 agonist that differs from racemic salbutamol by elimination of (S)-salbutamol. Levosalbutamol is an effective bronchodilator whose primary mechanism of action is unimpeded by (S) salbutamol. Thus, when compared with racemic salbutamol, clinically comparable bronchodilation can be achieved with doses that substantially lessen beta-mediated side effects. Levosalbutamol produces bronchodilatation through stimulation of beta-2-adrenergic receptors in bronchial smooth muscles, thereby causing relaxation of bronchial muscle fibres.

Composition

Purilin® 1 Tablet: Each tablet contains Levosalbutamol 1 mg as Levosalbutamol Sulphate INN.

Purilin® 2 Tablet: Each tablet contains Levosalbutamol 2 mg as Levosalbutamol Sulphate INN.

Purilin® Syrup: Each 5 ml syrup contains Levosalbutamol 1 mg as Levosalbutamol Sulphate INN.

Indications

Levosalbutamol is indicated for the treatment and prevention of bronchospasm in adults, adolescents, and children with reversible obstructive airway diseases.

Dosage and administration

Adults and adolescents above 12 years:

1-2 mg, three times daily.

Children aged 6-11 years:

5 ml (1 mg), three times daily.

Contraindications

Levosalbutamol is contraindicated in patients with a history of hypersensitivity to Levosalbutamol or any of its components.

Side effects

Hypocalcaemia, palpitation, fine tremors of the skeletal muscle and muscle cramps may occur. The other likely side effects are nausea, vomiting, burning substernal or epigastric pain and diarrhoea.

Use in pregnancy & lactation

Pregnancy: The drug should be used during pregnancy only if the potential benefit justifies the potential risk of the fetus.

Lactation: It is not known whether Levosalbutamol is excreted in human milk. Caution should be exercised when oral Levosalbutamol is administered to a nursing woman.

Precautions

Particular caution is advised in acute severe asthma as this effect may be potentiated by hypoxia and by concomitant treatment with xanthine derivatives, steroids and diuretics. Serum potassium levels should be monitored in such situations.

Drug interactions

Other short-acting sympathomimetic bronchodilators or epinephrine should be used with caution with Levosalbutamol. If additional adrenergic drugs are to be administered by any route, they should be used with caution to avoid deleterious cardiovascular effects.

Over dosage

The expected symptoms with over dosage are those of excessive beta-adrenergic stimulation and the symptoms listed under side effects. In the event of serious poisoning, the stomach should be emptied and, if necessary, a beta-blocker administered with caution in patients with a history of bronchospasm.

Storage

Store in a cool (Below 25° C temperature) and dry place protected from light.

Packaging

Purilin® 1 Tablet: Each carton containing 14X8 tablets in blister pack.

Purilin® 2 Tablet: Each carton containing 14X8 tablets in blister pack.

Purilin® 50 ml Syrup: Each glass bottle contains 50 ml syrup.

Purilin® 100 ml Syrup: Each glass bottle contains 100 ml syrup.

618-01



Manufactured by
Opsonin Pharma Limited
Rupatali, Barishal, Bangladesh.
® Registered Trade Mark.

